Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second ...

May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi is at a pivotal moment with promising data, a dedicated development team advancing trials, and a strong balance sheet to support the continued development of Haduvio." In March, Trevi ...

New Study Confirms That Many Disposable E-cigarettes Sold Today Come in Bigger Sizes and Are Cheaper Than Those Ever Sold Before WASHINGTON, May 5, 2025 /PRNewswire/ -- A new study published in ...

May 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...